Send to

Choose Destination
Hum Mol Genet. 2019 May 1;28(9):1429-1444. doi: 10.1093/hmg/ddy439.

Impact of Fgf10 deficiency on pulmonary vasculature formation in a mouse model of bronchopulmonary dysplasia.

Author information

International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University and Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China.
Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany.
University Children's Hospital Gießen, Department of General Pediatrics and Neonatology, Justus-Liebig-University, 35392 Gießen, Germany. Member of the German Lung Research Center (DZL), Universities of Gießen and Marburg Lung Center (UGMLC), Gießen, Germany.
Department of Radiology, Justus-Liebig-University, University Hospital Gießen, Gießen, Germany.
Max-Planck-Institute for Heart and Lung Research, Member of the German Lung Research Center (DZL), Bad Nauheim, Germany.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan , Russian Federation.
Division of Neonatology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Department of Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Department of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands.


Bronchopulmonary dysplasia (BPD), characterized by alveoli simplification and dysmorphic pulmonary microvasculature, is a chronic lung disease affecting prematurely born infants. Pulmonary hypertension (PH) is an important BPD feature associated with morbidity and mortality. In human BPD, inflammation leads to decreased fibroblast growth factor 10 (FGF10) expression but the impact on the vasculature is so far unknown. We used lungs from Fgf10+/- versus Fgf10+/+ pups to investigate the effect of Fgf10 deficiency on vascular development in normoxia (NOX) and hyperoxia (HOX, BPD mouse model). To assess the role of fibroblast growth factor receptor 2b (Fgfr2b) ligands independently of early developmentaldefects, we used an inducible double transgenic system in mice allowing inhibition of Fgfr2b ligands activity. Using vascular morphometry, we quantified the pathological changes. Finally, we evaluated changes in FGF10, surfactant protein C (SFTPC), platelet endothelial cell adhesion molecule (PECAM) and alpha-smooth muscle actin 2 (α-SMA) expression in human lung samples from patients suffering from BPD. In NOX, no major difference in the lung vasculature between Fgf10+/- and control pups was detected. In HOX, a greater loss of blood vessels in Fgf10+/- lungs is associated with an increase of poorly muscularized vessels. Fgfr2b ligands inhibition postnatally in HOX is sufficient to decrease the number of blood vessels while increasing the level of muscularization, suggesting a PH phenotype. BPD lungs exhibited decreased FGF10, SFTPC and PECAM but increased α-SMA. Fgf10 deficiency-associated vascular defects are enhanced in HOX and could represent an additional cause of morbidity in human patients with BPD.

[Available on 2020-05-01]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center